Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Binimetinib (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 Jun 2021 Results published in the Lung Cancer
- 29 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.